Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 June 2020Website:
http://www.legendbiotech.comNext earnings report:
15 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 19:42:37 GMTDividend
Analysts recommendations
Institutional Ownership
LEGN Latest News
SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without l.
Legend Biotech Corporation (NASDAQ: LEGN) held its Q1 2024 Earnings Call on May 13, 2024 at 8:00 AM ET. Key company representatives present included Jessie Yeung, Ying Huang, Lori Macomber, Guowei Fang, and Steve Gavel. Various analysts and investors also participated in the conference call.
Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The biotech industry is evolving rapidly, with 2024 poised to be a year of significant advancements and opportunities. Amidst an uncertain macroeconomic environment, the biotech sector is gaining momentum, fueled by groundbreaking innovations and favorable market conditions.
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2023 Earnings Conference March 11, 2024 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Guowei Fang - Chief Scientific Officer and Head of Business Development Steve Gavel - Senior Vice President, Commercial Development, US and Europe Conference Call Participants Jessica Fye - J.P. Morgan Jonathan Miller - Evercore ISI Ziyi Chen - Goldman Sachs Dave Windley - Jefferies Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Markets Ashwani Verma - UBS Edward Tenthoff - Piper Sandler Justin Zelin - BTIG Mitchell Kapoor - H.C.
Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the agreement, its Legend Biotech Ireland subsidiary has granted Novartis the rights to develop, manufacture and commercialize its CAR-T cell therapy candidate LB2102 and other potential chimeric antigen receptor T-cell therapies selectively targeting Delta-like ligand 3 (DLL3).
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal would translate to quarterly net sales of nearly $1 billion by Q4 2025.
Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, -0.20%, generated $117 million in sales in the second quarter. That represents a roughly 65% increase over the previous quarter, BMO Capital Markets analysts wrote in a research note Thursday, suggesting that the U.S. Food and Drug Administration has increased Carvykti's manufacturing cap.
What type of business is Legend Biotech?
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
What sector is Legend Biotech in?
Legend Biotech is in the Healthcare sector
What industry is Legend Biotech in?
Legend Biotech is in the Biotechnology industry
What country is Legend Biotech from?
Legend Biotech is headquartered in United States
When did Legend Biotech go public?
Legend Biotech initial public offering (IPO) was on 05 June 2020
What is Legend Biotech website?
https://www.legendbiotech.com
Is Legend Biotech in the S&P 500?
No, Legend Biotech is not included in the S&P 500 index
Is Legend Biotech in the NASDAQ 100?
No, Legend Biotech is not included in the NASDAQ 100 index
Is Legend Biotech in the Dow Jones?
No, Legend Biotech is not included in the Dow Jones index
When does Legend Biotech report earnings?
The next expected earnings date for Legend Biotech is 15 August 2024